{"protocolSection":{"identificationModule":{"nctId":"NCT01323270","orgStudyIdInfo":{"id":"B1971010"},"secondaryIdInfos":[{"id":"6108A1-2008","type":"OTHER","domain":"Alias Study Number"},{"id":"2010-022449-38","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.","officialTitle":"A Phase 2, Randomized, Placebo-controlled, Single-blind Trial To Assess The Safety, Tolerability, And Immunogenicity Of Repevax(Registered) And Bivalent Rlp2086 Vaccine When Administered Concomitantly In Healthy Subjects Aged Greater Than Or Equal To 11 To <19 Years"},"statusModule":{"statusVerifiedDate":"2022-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-03-18","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2012-10-08","type":"ACTUAL"},"completionDateStruct":{"date":"2013-02-19","type":"ACTUAL"},"studyFirstSubmitDate":"2011-02-17","studyFirstSubmitQcDate":"2011-03-24","studyFirstPostDateStruct":{"date":"2011-03-25","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-11-21","resultsFirstSubmitQcDate":"2014-11-21","resultsFirstPostDateStruct":{"date":"2014-11-26","type":"ESTIMATED"},"lastUpdateSubmitDate":"2022-10-26","lastUpdatePostDateStruct":{"date":"2022-10-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This study is to look at a new vaccine that might prevent meningococcal disease, and to look at the safety of the new vaccine as well as how it is tolerated when given together with Repevax. The study will be done in healthy adolescents."},"conditionsModule":{"conditions":["Meningococcal Vaccine","rLP2086","Repevax","N Meningitidis Serogroup B","Meningitis"],"keywords":["Healthy adolescents"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"SINGLE","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":753,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"rLP2086","type":"EXPERIMENTAL","description":"rLP2086 and Repevax","interventionNames":["Biological: rLP2086","Biological: Repevax"]},{"label":"Saline and Repevax","type":"PLACEBO_COMPARATOR","description":"Saline and Repevax","interventionNames":["Biological: Saline","Biological: Repevax"]}],"interventions":[{"type":"BIOLOGICAL","name":"rLP2086","description":"0.5 mL dose, given at 0, 2 and 6 months.","armGroupLabels":["rLP2086"]},{"type":"BIOLOGICAL","name":"Repevax","description":"0.5 mL dose, given at 0 months.","armGroupLabels":["rLP2086"]},{"type":"BIOLOGICAL","name":"Saline","description":"0.5 mL dose, given at 0, 2 and 6 months.","armGroupLabels":["Saline and Repevax"]},{"type":"BIOLOGICAL","name":"Repevax","description":"0.5 mL dose, given at 0 months.","armGroupLabels":["Saline and Repevax"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants Achieving Prespecified Criteria for the Concomitant Antigen","timeFrame":"1 month after Vaccination 1"},{"measure":"Percentage of Participants With at Least One Adverse Event (AE)","timeFrame":"Vaccination 1 up to 1 month after Vaccination 3"}],"secondaryOutcomes":[{"measure":"Geometric Mean Concentration (GMC) for Diphtheria and Tetanus Antigens","timeFrame":"1 month after Vaccination 1"},{"measure":"GMC for Acellular Pertussis Antigens","description":"Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EU/mL)","timeFrame":"1 month after Vaccination 1"},{"measure":"Geometric Mean Titer (GMT) for Poliomyelitis Antigens","timeFrame":"1 month after Vaccination 1"},{"measure":"Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal to (>=) Prespecified Titer Level","timeFrame":"1 month after Vaccination 3"}],"otherOutcomes":[{"measure":"Immunoglobulin G (IgG) Measured by Geometric Mean Titer (GMT)","timeFrame":"Before vaccination 1, 1 month after Vaccination 2, 3"},{"measure":"Geometric Mean Fold-Rise (GMFR) for IgG","timeFrame":"Before Vaccination 1, 1 month after Vaccination 2, 3"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Evidence of a personally signed and dated informed consent document indicating that the parent/legally acceptable representative and/or subject has been informed of all pertinent aspects of the study.\n* Parent/legally acceptable representative and/or subjects who are willing and able to comply with scheduled visits, laboratory tests, and other study procedures.\n* Male or female subject aged ≥11 and \\<19 years at the time of enrollment.\n* Available for the entire study period and can be reached by telephone.\n* Healthy subject as determined by medical history, physical examination, and judgment of the investigator.\n* Has received full series of diphtheria, tetanus, and pertussis (DTP)/DTaP vaccines and oral poliomyelitis virus (OPV)/IPV vaccines per country-specific recommendations applicable at the time of receipt.\n* All male and female subjects must agree to practice a form of effective contraception, such as barrier contraception (ie, condom plus spermicide, a female condom, diaphragm, cervical cap or intrauterine device), implants, injectables, combined oral contraceptives or sexual abstinence prior to entering into the study, for the duration of the vaccination period and for 28 days after the last study vaccination. For Germany: The phrase sexual abstinence is not applicable, with the understanding that all male and all female subjects of childbearing potential must practice an effective form of contraception during the study.\n* Negative urine pregnancy test for female subjects.\n\nExclusion Criteria:\n\n* Previous vaccination with any meningococcal serogroup B vaccine.\n* Vaccination with any diphtheria, tetanus, pertussis, or poliomyelitis virus vaccine within 5 years of the first study vaccination.\n* A previous anaphylactic reaction to any vaccine or vaccine-related component.\n* Contraindication to vaccination with diphtheria, tetanus, pertussis, or poliomyelitis virus vaccine.\n* Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.\n* A known or suspected disease of the immune system or those receiving immunosuppressive therapy.\n* History of culture-proven disease caused by Neisseria meningitidis or Neisseria gonorrhoeae.\n* Significant neurological disorder or history of seizure (excluding simple febrile seizure).\n* Receipt of any blood products, including immunoglobulin within 6 months before the first study vaccination.\n* Current chronic use of systemic antibiotics.\n* Participation in other studies during study participation. Participation in purely observational studies is acceptable.\n* Received any investigational drugs, vaccines or devices within 28 days before administration of the first study vaccination.\n* Any neuroinflammatory or autoimmune condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.\n* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.\n* Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.\n* Subject is a direct descendant (eg, child, grandchild or other family member) of study site or Pfizer personnel.\n* Subject is pregnant or breastfeeding.","healthyVolunteers":true,"sex":"ALL","minimumAge":"11 Years","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Espoo Vaccine Research Clinic","city":"Espoo","zip":"02100","country":"Finland","geoPoint":{"lat":60.2052,"lon":24.6522}},{"facility":"Helsinki South Vaccine Research Clinic","city":"Helsinki","zip":"00100","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"Ita-Helsinki Vaccine Research Clinic","city":"Helsinki","zip":"00930","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"Järvenpää Vaccine Research Clinic","city":"Jarvenpaa","zip":"04400","country":"Finland","geoPoint":{"lat":60.47369,"lon":25.08992}},{"facility":"Kokkola Vaccine Research Clinic","city":"Kokkola","zip":"67100","country":"Finland","geoPoint":{"lat":63.83847,"lon":23.13066}},{"facility":"Lahti Vaccine Research Clinic","city":"Lahti","zip":"15140","country":"Finland","geoPoint":{"lat":60.98267,"lon":25.66151}},{"facility":"Oulu Vaccine Research Clinic","city":"Oulu","zip":"90220","country":"Finland","geoPoint":{"lat":65.01236,"lon":25.46816}},{"facility":"Pori Vaccine Research Clinic","city":"Pori","zip":"28100","country":"Finland","geoPoint":{"lat":61.48072,"lon":21.78518}},{"facility":"Seinäjoki Vaccine Research Clinic","city":"Seinäjoki","zip":"60100","country":"Finland","geoPoint":{"lat":62.79446,"lon":22.82822}},{"facility":"Tampereen Yliopisto University Of Tampere","city":"Tampere","zip":"33014","country":"Finland","geoPoint":{"lat":61.49911,"lon":23.78712}},{"facility":"Tampere Vaccine Research Clinic","city":"Tampere","zip":"33100","country":"Finland","geoPoint":{"lat":61.49911,"lon":23.78712}},{"facility":"Vaccine Research Center","city":"Tampere","zip":"FIN-33014","country":"Finland","geoPoint":{"lat":61.49911,"lon":23.78712}},{"facility":"Turku Vaccine Research Clinic","city":"Turku","zip":"20520","country":"Finland","geoPoint":{"lat":60.45148,"lon":22.26869}},{"facility":"Vantaa Vaccine Research Clinic","city":"Vantaa","zip":"01300","country":"Finland","geoPoint":{"lat":60.29414,"lon":25.04099}},{"facility":"Gemeinschaftspraxis Dr. med. Guido Hein, Dr. med. Rainer Lauf","city":"Bad Sobernheim","zip":"55566","country":"Germany","geoPoint":{"lat":49.78636,"lon":7.65146}},{"facility":"Gerhard Bleckmann Kinder- und Jugendarzt","city":"Baunatal","zip":"34225","country":"Germany","geoPoint":{"lat":51.25182,"lon":9.40747}},{"facility":"Kinderarzt-Praxis","city":"Bramsche","zip":"49565","country":"Germany","geoPoint":{"lat":52.40881,"lon":7.97288}},{"facility":"Gemeinschaftspraxis fuer Kinder- und Jugendmedizin Dres. Behre, Burgert, Gunkel","city":"Kehl","zip":"77694","country":"Germany","geoPoint":{"lat":48.57297,"lon":7.81523}},{"facility":"Dr. med. Sobhi Mahdi Kinderarzt und Jugendmedizin","city":"Lübeck","zip":"23566","country":"Germany","geoPoint":{"lat":53.86893,"lon":10.68729}},{"facility":"Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz","city":"Mainz","zip":"55131","country":"Germany","geoPoint":{"lat":49.98185,"lon":8.28008}},{"facility":"Dr. Michael Vomstein, Hermann Oesterle, Kinder- und Jugendaerzte","city":"Schwäbisch Hall","zip":"74523","country":"Germany","geoPoint":{"lat":49.11127,"lon":9.73908}},{"facility":"Thomas Lenz & (Frau) Dr. med. Marin Eggers","city":"Vellmar","zip":"34246","country":"Germany","geoPoint":{"lat":51.35806,"lon":9.47974}},{"facility":"Dres.T. Schmitz, H. Knee, Ch, Wittermann Fachaerztliche","city":"Weilheim","zip":"82362","country":"Germany","geoPoint":{"lat":47.84147,"lon":11.15484}},{"facility":"Gemeinschaftspraxis fuer Kinder und Jugendliche Welzheim","city":"Welzheim","zip":"73642","country":"Germany","geoPoint":{"lat":48.87675,"lon":9.63434}},{"facility":"Gabinet Lekarski","city":"Dębica","zip":"39-200","country":"Poland","geoPoint":{"lat":50.05146,"lon":21.41141}},{"facility":"Krakowski Szpital Specjalistyczny, im. Jana Pawla II","city":"Krakow","zip":"31-202","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Specjalistyczna Praktyka Lekarska Gravita","city":"Lodz","zip":"91-347","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Oddzial Pediatryczny","city":"Lubartów","zip":"21-100","country":"Poland","geoPoint":{"lat":51.46026,"lon":22.60952}},{"facility":"NZOZ Praktyka Lekarza Rodzinnego Eskulap","city":"Lublin","zip":"20-044","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"NZOZ Praktyka Lekarza Rodzinnego Alina Grocka-Wlazlak","city":"Oborniki Śląskie","zip":"55-120","country":"Poland","geoPoint":{"lat":51.30137,"lon":16.91465}},{"facility":"Specjalistyczny ZOZ nad Matka i Dzieckiem, Przychodnia Wieku Rozwojowego","city":"Poznan","zip":"61-825","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"NZLA Michalkowice Jarosz i Partnerzy","city":"Siemianowice Śląskie","zip":"41-103","country":"Poland","geoPoint":{"lat":50.32738,"lon":19.02901}},{"facility":"NZOZ Nasz Lekarz","city":"Torun","zip":"87-100","country":"Poland","geoPoint":{"lat":53.01375,"lon":18.59814}},{"facility":"Szpital im. Sw. Jadwigi Slaskiej, Oddzial Pediatryczny","city":"Trzebnica","zip":"55-100","country":"Poland","geoPoint":{"lat":51.31076,"lon":17.06331}},{"facility":"Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu","city":"Wroclaw","zip":"50-345","country":"Poland","geoPoint":{"lat":51.10286,"lon":17.03006}},{"facility":"NZOZ Salmed","city":"Łęczna","zip":"21-010","country":"Poland","geoPoint":{"lat":51.30121,"lon":22.88135}}]},"referencesModule":{"references":[{"pmid":"35164991","type":"DERIVED","citation":"Beeslaar J, Mather S, Absalon J, Eiden JJ, York LJ, Crowther G, Maansson R, Maguire JD, Peyrani P, Perez JL. Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older. Vaccine. 2022 Mar 15;40(12):1872-1878. doi: 10.1016/j.vaccine.2022.01.046. Epub 2022 Feb 11."},{"pmid":"32681472","type":"DERIVED","citation":"Beeslaar J, Peyrani P, Absalon J, Maguire J, Eiden J, Balmer P, Maansson R, Perez JL. Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data. Infect Dis Ther. 2020 Sep;9(3):625-639. doi: 10.1007/s40121-020-00322-5. Epub 2020 Jul 17."},{"pmid":"26803328","type":"DERIVED","citation":"Vesikari T, Wysocki J, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O'Neill RE, York LJ, Perez JL. Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents. J Pediatric Infect Dis Soc. 2016 Jun;5(2):180-7. doi: 10.1093/jpids/piv064. Epub 2016 Jan 23."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 753 participants were enrolled in this study. Of these, 4 participants were not randomized but were vaccinated rLP2086 vaccine or Repevax or Saline at Vaccination 1. These participants were included in safety population and not intent-to-treat population.","groups":[{"id":"FG000","title":"Group 1: rLP2086 + Repevax","description":"Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month."},{"id":"FG001","title":"Group 2: Saline+Repevax","description":"Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"373"},{"groupId":"FG001","numSubjects":"376"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"330"},{"groupId":"FG001","numSubjects":"347"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"43"},{"groupId":"FG001","numSubjects":"29"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Not eligible","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Randomized, but not vaccinated","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Group 1: rLP2086 + Repevax","description":"Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month."},{"id":"BG001","title":"Group 2: Saline+Repevax","description":"Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"373"},{"groupId":"BG001","value":"376"},{"groupId":"BG002","value":"749"}]}],"measures":[{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Greater than or equal (>=)11-less than (<)14years","categories":[{"measurements":[{"groupId":"BG000","value":"217"},{"groupId":"BG001","value":"215"},{"groupId":"BG002","value":"432"}]}]},{"title":">=14 years-<19 years","categories":[{"measurements":[{"groupId":"BG000","value":"156"},{"groupId":"BG001","value":"161"},{"groupId":"BG002","value":"317"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"183"},{"groupId":"BG001","value":"184"},{"groupId":"BG002","value":"367"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"190"},{"groupId":"BG001","value":"192"},{"groupId":"BG002","value":"382"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Prespecified Criteria for the Concomitant Antigen","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"1 month after Vaccination 1","groups":[{"id":"OG000","title":"Group 1: rLP2086 + Repevax","description":"Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month."},{"id":"OG001","title":"Group 2: Saline+Repevax","description":"Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"348"}]}],"classes":[{"title":"Diphtheria","categories":[{"measurements":[{"groupId":"OG000","value":"99.4"},{"groupId":"OG001","value":"99.4"}]}]},{"title":"Tetanus","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}]},{"title":"Pertussis toxoid","categories":[{"measurements":[{"groupId":"OG000","value":"94.7"},{"groupId":"OG001","value":"96.0"}]}]},{"title":"Pertussis filamentous hemagglutinin","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}]},{"title":"Pertussis pertactin","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}]},{"title":"Pertussis fimbrial agglutinogens types 2+3","categories":[{"measurements":[{"groupId":"OG000","value":"97.6"},{"groupId":"OG001","value":"98.9"}]}]},{"title":"Poliovirus type 1","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}]},{"title":"Poliovirus type 2","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}]},{"title":"Poliovirus type 3","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Diphtheria: Exact 2-sided confidence interval (based on Chan and Zhang) was reported for the difference in proportions, expressed as a percentage.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE_LEGACY","nonInferiorityComment":"The non-inferiority criteria margin was 10%.","paramType":"Percent difference","paramValue":"-0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.6","ciUpperLimit":"1.5"},{"groupIds":["OG000","OG001"],"groupDescription":"Tetanus: Exact 2-sided confidence interval (based on Chan and Zhang) was reported for the difference in proportions, expressed as a percentage.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE_LEGACY","nonInferiorityComment":"The non-inferiority criteria margin was 10%.","paramType":"Percent difference","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.1","ciUpperLimit":"1.1"},{"groupIds":["OG000","OG001"],"groupDescription":"Pertussis toxoid: Exact 2-sided confidence interval (based on Chan and Zhang) was reported for the difference in proportions, expressed as a percentage.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE_LEGACY","nonInferiorityComment":"The non-inferiority criteria margin was 10%.","paramType":"Percent difference","paramValue":"-1.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.7","ciUpperLimit":"1.9"},{"groupIds":["OG000","OG001"],"groupDescription":"Pertussis filamentous hemagglutinin: Exact 2-sided confidence interval (based on Chan and Zhang) was reported for the difference in proportions, expressed as a percentage.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE_LEGACY","nonInferiorityComment":"The non-inferiority criteria margin was 10%.","paramType":"Percent difference","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.1","ciUpperLimit":"1.1"},{"groupIds":["OG000","OG001"],"groupDescription":"Pertussis pertactin: Exact 2-sided confidence interval (based on Chan and Zhang) was reported for the difference in proportions, expressed as a percentage.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE_LEGACY","nonInferiorityComment":"The non-inferiority criteria margin was 10%.","paramType":"Percent difference","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.1","ciUpperLimit":"1.1"},{"groupIds":["OG000","OG001"],"groupDescription":"Pertussis fimbrial agglutinogens types 2+3: Exact 2-sided confidence interval (based on Chan and Zhang) was reported for the difference in proportions, expressed as a percentage.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE_LEGACY","nonInferiorityComment":"The non-inferiority criteria margin was 10%.","paramType":"Percent difference","paramValue":"-1.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.6","ciUpperLimit":"0.8"},{"groupIds":["OG000","OG001"],"groupDescription":"Poliovirus type 1: Exact 2-sided confidence interval (based on Chan and Zhang) was reported for the difference in proportions, expressed as a percentage.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE_LEGACY","nonInferiorityComment":"The non-inferiority criteria margin was 10%.","paramType":"Percent difference","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.1","ciUpperLimit":"1.1"},{"groupIds":["OG000","OG001"],"groupDescription":"Poliovirus type 2: Exact 2-sided confidence interval (based on Chan and Zhang) was reported for the difference in proportions, expressed as a percentage.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE_LEGACY","nonInferiorityComment":"The non-inferiority criteria margin was 10%.","paramType":"Percent difference","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.1","ciUpperLimit":"1.1"},{"groupIds":["OG000","OG001"],"groupDescription":"Poliovirus type 3: Exact 2-sided confidence interval (based on Chan and Zhang) was reported for the difference in proportions, expressed as a percentage.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE_LEGACY","nonInferiorityComment":"The non-inferiority criteria margin was 10%.","paramType":"Percent difference","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.1","ciUpperLimit":"1.1"}]},{"type":"SECONDARY","title":"Geometric Mean Concentration (GMC) for Diphtheria and Tetanus Antigens","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"International Units per milliliter","timeFrame":"1 month after Vaccination 1","groups":[{"id":"OG000","title":"Group 1: rLP2086 + Repevax","description":"Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month."},{"id":"OG001","title":"Group 2: Saline+Repevax","description":"Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"348"}]}],"classes":[{"title":"Diphtheria","categories":[{"measurements":[{"groupId":"OG000","value":"1.4","lowerLimit":"1.28","upperLimit":"1.55"},{"groupId":"OG001","value":"1.5","lowerLimit":"1.34","upperLimit":"1.63"}]}]},{"title":"Tetanus","categories":[{"measurements":[{"groupId":"OG000","value":"12.3","lowerLimit":"11.50","upperLimit":"13.11"},{"groupId":"OG001","value":"12.4","lowerLimit":"11.52","upperLimit":"13.25"}]}]}]},{"type":"SECONDARY","title":"GMC for Acellular Pertussis Antigens","description":"Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EU/mL)","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EU/mL","timeFrame":"1 month after Vaccination 1","groups":[{"id":"OG000","title":"Group 1: rLP2086 + Repevax","description":"Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month."},{"id":"OG001","title":"Group 2: Saline+Repevax","description":"Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"348"}]}],"classes":[{"title":"Pertussis toxoid","categories":[{"measurements":[{"groupId":"OG000","value":"27.1","lowerLimit":"24.45","upperLimit":"30.07"},{"groupId":"OG001","value":"26.5","lowerLimit":"23.95","upperLimit":"29.38"}]}]},{"title":"Pertussis filamentous hemagglutinin","categories":[{"measurements":[{"groupId":"OG000","value":"119.4","lowerLimit":"111.15","upperLimit":"128.17"},{"groupId":"OG001","value":"122.9","lowerLimit":"115.14","upperLimit":"131.13"}]}]},{"title":"Pertussis pertactin","categories":[{"measurements":[{"groupId":"OG000","value":"317.0","lowerLimit":"285.64","upperLimit":"351.80"},{"groupId":"OG001","value":"336.1","lowerLimit":"305.82","upperLimit":"369.30"}]}]},{"title":"Pertussis fimbrial agglutinogens types 2+3","categories":[{"measurements":[{"groupId":"OG000","value":"339.1","lowerLimit":"296.35","upperLimit":"387.94"},{"groupId":"OG001","value":"364.5","lowerLimit":"320.62","upperLimit":"414.42"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer (GMT) for Poliomyelitis Antigens","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"1 month after Vaccination 1","groups":[{"id":"OG000","title":"Group 1: rLP2086 + Repevax","description":"Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month."},{"id":"OG001","title":"Group 2: Saline+Repevax","description":"Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"348"}]}],"classes":[{"title":"Poliovirus type 1","categories":[{"measurements":[{"groupId":"OG000","value":"662.1","lowerLimit":"567.36","upperLimit":"772.67"},{"groupId":"OG001","value":"672.6","lowerLimit":"581.87","upperLimit":"777.55"}]}]},{"title":"Poliovirus type 2","categories":[{"measurements":[{"groupId":"OG000","value":"840.5","lowerLimit":"725.11","upperLimit":"974.29"},{"groupId":"OG001","value":"995.8","lowerLimit":"860.54","upperLimit":"1152.41"}]}]},{"title":"Poliovirus type 3","categories":[{"measurements":[{"groupId":"OG000","value":"2237.4","lowerLimit":"1945.81","upperLimit":"2572.65"},{"groupId":"OG001","value":"2450.1","lowerLimit":"2152.60","upperLimit":"2788.70"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal to (>=) Prespecified Titer Level","populationDescription":"Serum samples from approximately 50% of the participants had hSBA performed with primary MnB test strains expressing rLP2086 variants A22 and B24 and the other 50% of participants had hSBAs performed with strains expressing variants A56 and B44. The number of participants shown for each test strain represents the number with valid and determinant assay result for that strain.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"1 month after Vaccination 3","groups":[{"id":"OG000","title":"Group 1: rLP2086 + Repevax","description":"Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month."},{"id":"OG001","title":"Group 2: Saline+Repevax","description":"Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"307"},{"groupId":"OG001","value":"330"}]}],"classes":[{"title":"PMB80 [A22] 1:16 (N=158, 166)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.6"},{"groupId":"OG001","value":"19.9"}]}]},{"title":"PMB2001 [A56] 1:8 (N=148, 152)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"152"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"26.3"}]}]},{"title":"PMB2948 [B24] 1:8 (N=157, 170)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"170"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.8"},{"groupId":"OG001","value":"12.9"}]}]},{"title":"PMB2707 [B44] 1:8 (N=146, 159)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81.5"},{"groupId":"OG001","value":"8.2"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Immunoglobulin G (IgG) Measured by Geometric Mean Titer (GMT)","populationDescription":"A decision was made, a priori, that the hSBA MnB immunogenicity assay will be used instead of the IgG assay originally planned . Therefore only hSBA assay results will be disclosed.","reportingStatus":"POSTED","timeFrame":"Before vaccination 1, 1 month after Vaccination 2, 3","groups":[{"id":"OG000","title":"Group 1: rLP2086 + Repevax","description":"Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month."},{"id":"OG001","title":"Group 2: Saline+Repevax","description":"Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Geometric Mean Fold-Rise (GMFR) for IgG","populationDescription":"A decision was made, a priori, that the hSBA MnB immunogenicity assay will be used instead of the IgG assay originally planned . Therefore only hSBA assay results will be disclosed.","reportingStatus":"POSTED","timeFrame":"Before Vaccination 1, 1 month after Vaccination 2, 3","groups":[{"id":"OG000","title":"Group 1: rLP2086 + Repevax","description":"Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month."},{"id":"OG001","title":"Group 2: Saline+Repevax","description":"Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least One Adverse Event (AE)","populationDescription":"Summary was performed for participants as per vaccine administration.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Vaccination 1 up to 1 month after Vaccination 3","groups":[{"id":"OG000","title":"Group 1: rLP2086 + Repevax","description":"Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month."},{"id":"OG001","title":"Group 2: Saline+Repevax","description":"Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"378"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.4"},{"groupId":"OG001","value":"40.2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"AE reported from Vaccination 1 to 1 month after last administration of investigational product (bivalent rLP2086/saline/Repevax). SAE reported from Vaccination 1 to 6 months after last of investigational product (bivalent rLP2086/saline/Repevax).","description":"Events collected on case report form were reported. Summary was performed for participants as per vaccine administration.","eventGroups":[{"id":"EG000","title":"Group 1: rLP2086 + Repevax","description":"Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month.","seriousNumAffected":12,"seriousNumAtRisk":374,"otherNumAffected":98,"otherNumAtRisk":374},{"id":"EG001","title":"Group 2: Saline+Repevax","description":"Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month.","seriousNumAffected":9,"seriousNumAtRisk":378,"otherNumAffected":118,"otherNumAtRisk":378}],"seriousEvents":[{"term":"Idiopathic thrombocytopenic purpura","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":374},{"groupId":"EG001","numAffected":0,"numAtRisk":378}]},{"term":"Syndactyly","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":374},{"groupId":"EG001","numAffected":1,"numAtRisk":378}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":374},{"groupId":"EG001","numAffected":0,"numAtRisk":378}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":374},{"groupId":"EG001","numAffected":2,"numAtRisk":378}]},{"term":"Abdominal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":374},{"groupId":"EG001","numAffected":0,"numAtRisk":378}]},{"term":"Appendicitis perforated","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":374},{"groupId":"EG001","numAffected":0,"numAtRisk":378}]},{"term":"Arthritis infective","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":374},{"groupId":"EG001","numAffected":0,"numAtRisk":378}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":374},{"groupId":"EG001","numAffected":0,"numAtRisk":378}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":374},{"groupId":"EG001","numAffected":0,"numAtRisk":378}]},{"term":"Peritonsillar abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":374},{"groupId":"EG001","numAffected":1,"numAtRisk":378}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":374},{"groupId":"EG001","numAffected":0,"numAtRisk":378}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":374},{"groupId":"EG001","numAffected":0,"numAtRisk":378}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":374},{"groupId":"EG001","numAffected":1,"numAtRisk":378}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":374},{"groupId":"EG001","numAffected":1,"numAtRisk":378}]},{"term":"Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":374},{"groupId":"EG001","numAffected":1,"numAtRisk":378}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":374},{"groupId":"EG001","numAffected":1,"numAtRisk":378}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":374},{"groupId":"EG001","numAffected":0,"numAtRisk":378}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":374},{"groupId":"EG001","numAffected":0,"numAtRisk":378}]},{"term":"Hydrocephalus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":374},{"groupId":"EG001","numAffected":0,"numAtRisk":378}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":374},{"groupId":"EG001","numAffected":1,"numAtRisk":378}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":374},{"groupId":"EG001","numAffected":1,"numAtRisk":378}]},{"term":"Drug abuse","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":374},{"groupId":"EG001","numAffected":1,"numAtRisk":378}]},{"term":"Ovarian cyst ruptured","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":374},{"groupId":"EG001","numAffected":1,"numAtRisk":378}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":374},{"groupId":"EG001","numAffected":1,"numAtRisk":378}]}],"otherEvents":[{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":374},{"groupId":"EG001","numAffected":3,"numAtRisk":378}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":374},{"groupId":"EG001","numAffected":3,"numAtRisk":378}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":374},{"groupId":"EG001","numAffected":4,"numAtRisk":378}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":374},{"groupId":"EG001","numAffected":4,"numAtRisk":378}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":374},{"groupId":"EG001","numAffected":0,"numAtRisk":378}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":374},{"groupId":"EG001","numAffected":0,"numAtRisk":378}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":30,"numAtRisk":374},{"groupId":"EG001","numAffected":31,"numAtRisk":378}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":374},{"groupId":"EG001","numAffected":19,"numAtRisk":378}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":374},{"groupId":"EG001","numAffected":19,"numAtRisk":378}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":374},{"groupId":"EG001","numAffected":18,"numAtRisk":378}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":374},{"groupId":"EG001","numAffected":11,"numAtRisk":378}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":374},{"groupId":"EG001","numAffected":6,"numAtRisk":378}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":374},{"groupId":"EG001","numAffected":7,"numAtRisk":378}]},{"term":"Acute tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":374},{"groupId":"EG001","numAffected":7,"numAtRisk":378}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":374},{"groupId":"EG001","numAffected":7,"numAtRisk":378}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":374},{"groupId":"EG001","numAffected":4,"numAtRisk":378}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":374},{"groupId":"EG001","numAffected":3,"numAtRisk":378}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":374},{"groupId":"EG001","numAffected":7,"numAtRisk":378}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":374},{"groupId":"EG001","numAffected":9,"numAtRisk":378}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":374},{"groupId":"EG001","numAffected":6,"numAtRisk":378}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer, Inc.","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D008581","term":"Meningitis"}],"ancestors":[{"id":"D000090862","term":"Neuroinflammatory Diseases"},{"id":"D009422","term":"Nervous System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C484699","term":"factor H-binding protein, Neisseria meningitidis"},{"id":"D012965","term":"Sodium Chloride"}],"ancestors":[{"id":"D002712","term":"Chlorides"},{"id":"D006851","term":"Hydrochloric Acid"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017670","term":"Sodium Compounds"}]}},"hasResults":true}